CompletedNCT00191633
Atomoxetine and the link between ADHD symptoms and daily functioning in children
About this title
Read the official source — NCT00191633Medication studyAges 6–11Canada
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
- Listed locations
- Calgary and 18 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 200
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 6 Years to 11 Years
- Official registry ID
- NCT00191633
- Official title
Show the full official title
A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Calgary · Edmonton · Abbotsford British Columbia
16 more locations
- Burnaby
- Kelowna
- Langley
- Vancouver
- Winnipeg
- Moncton
- Saint John
- Halifax
- Markham
- Niagara Falls
- Oshawa
- Pickering
- Toronto
- Whitby
- Summerside
- Saskatoon
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
